LIFE Nasdaq 2020 - 04 - 21

aTyr Pharma, Inc.

LIFE | $1.6 -1.23% -1.57% 290K

(0.0% 1d) (-16.4% 1m) (-20.8% 1y) (0.0% 2d) (-1.2% 3d) (0.0% 7d) (20.86% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 108,705,346
http://www.atyrpharma.com
Sec Filling | Patents | 44 employees

(US) aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

glass diagnostics

add to watch list Paper trade email alert is off

Press-releases

aTyr Pharma to Participate in April Investor Conferences
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| -19.6% | O: -1.01% H: 0.0% C: -3.05%
pharma

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| -1.23% | O: 0.0% H: 24.07% C: 22.84%
pharma year update results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| -20.0% | O: 0.0% H: 1.5% C: -5.0%
pharma conference year financial results

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| -14.89% | O: 1.6% H: 5.24% C: 3.14%
pharma program trial

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| 1.27% | O: 0.0% H: 3.16% C: 2.53%
pharma cell

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
Published: 2024-01-18 (Crawled : 13:00) - globenewswire.com
WDAY A | $255.74 -0.42% -0.43% 960K

Technology Services

| -9.09% | O: 0.71% H: 0.87% C: 0.84%
PODD | $167.25 -0.01% -0.03% 660K

Health Technology

| -16.75% | O: 0.95% H: 0.87% C: 0.54%
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| 9.97% | O: 1.72% H: 0.0% C: -4.05%
pharma

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| 42.86% | O: -1.79% H: 6.36% C: 1.36%
pharma preclinical efzofitimod

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| 39.13% | O: 0.87% H: 0.86% C: -3.45%
pharma update results

Sarcoidosis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Key Players - Pfizer, United Therapeutics, Xentria, aTyr Pharma, Kyorin Pharmaceutical, Novartis, Kinevant Sciences
Published: 2023-11-02 (Crawled : 21:00) - prnewswire.com
UTHR | $237.0 1.08% 1.09% 670K

Health Technology

| 3.87% | O: 0.73% H: 0.63% C: -2.35%
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| 24.03% | O: 0.78% H: 1.54% C: 0.0%
sciences growth market

aTyr Pharma to Present at November Investor Conferences
Published: 2023-11-01 (Crawled : 12:00) - globenewswire.com
LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

| 28.0% | O: 5.6% H: 0.0% C: -6.82%
pharma

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-24-002949	4	2024-02-07	2024-02-05	Sell	M	10375	20750
0001209191-24-002949	4	2024-02-07	2024-02-05	Buy	M	10375	116548
0001209191-24-002947	4	2024-02-07	2024-02-05	Sell	M	3750	7500
0001209191-24-002947	4	2024-02-07	2024-02-06	Sell	S	1590	20821
0001209191-24-002947	4	2024-02-07	2024-02-05	Buy	M	3750	22411
0001209191-24-002945	4	2024-02-07	2024-02-05	Sell	M	2688	5374
0001209191-24-002945	4	2024-02-07	2024-02-05	Buy	M	2688	14767
0001209191-24-001302	4	2024-01-10	2024-01-05	Buy	A	600000	600000